CRDMO INDUSTRY GROWTH
Cohance Lifesciences and other pharma stocks jump up to 5% after Jefferies initiates Buy recommendation
Cohance Lifesciences, Divi’s Laboratories, and SAI Life Sciences rallied after Jefferies initiated coverage with ‘Buy’ ratings, citing strong growth prospects in India’s CRDMO sector. The brokerage sees a high-teen revenue CAGR, led by China+1 diversification, pipeline visibility, and demand for diabetes and weight-loss therapies.
Anthem Biosciences IPO subscribed 4x on last day; Check GMP, and other key details
Anthem Biosciences IPO GMP: The IPO attracted strong interest, receiving bids for 17.66 crore shares against 4.4 crore shares on offer. Non-institutional investors (NIIs) led the demand, subscribing 12.37 times their allotted quota. The retail segment saw 2.38 times subscription, while qualified institutional buyers (QIBs) subscribed to 60% of their portion.
Anthem Biosciences IPO subscribed 2x on day 2; Check GMP, and other key details
Anthem Biosciences' IPO witnessed strong investor interest, being oversubscribed 2.08 times on Day 2, driven by NIIs. Brokerages recommend subscribing, citing the company's robust position and high-margin business model. The IPO, valued at a P/E ratio of 71x, closes on July 16, offering a compelling long-term growth opportunity in the CRDMO segment.
Anthem Biosciences' Rs 3,395 crore IPO opens for subscription. Should you bid?
Anthem Biosciences launched its IPO on July 14, featuring an offer for sale of Rs 3,395 crore. The Bengaluru-based CRDMO, with a price band of Rs 540–570 per share, boasts integrated capabilities in both small and large molecules. Analysts recommend subscribing, citing its strong market position, revenue visibility, and high-margin business model.
India's CRDMO sector can touch USD 25 bn in size by 2035: Report
India's CRDMO sector has the potential to reach USD 22-25 billion by 2035, driven by supply chain de-risking, pricing pressures, and demand for advanced modalities. However, challenges include talent expansion, faster regulatory approvals, and investment constraints. With investments in infrastructure, talent, and policy simplifications, India could become a global CRDMO leader.
India becoming an attractive option for global pharmaceutical supply chain: Macquarie Report
India's CRDMO industry is projected to grow from USD 7 billion to USD 14 billion by 2028, driven by pharmaceutical outsourcing and regulatory support. The industry's growth could reach a high-teens CAGR due to factors like the US Biosecure Act, potentially pushing it to USD 22 billion by 2030.
- Go To Page 1
Macquarie bullish on Suven Pharma, Divi's Labs, Bluejet and Syngene
Macquarie said that the sector is currently at a turning point, driven by increased pharmaceutical outsourcing due to drug pricing pressures and geopolitical factors, prompting a global restructuring of the pharmaceutical supply chain.
Macquarie initiates coverage on Divi’s Labs, 3 CRDMO firms with up to 40% upside potential
The global brokerage firm highlights that Indian CDMO companies trade at a 2-year forward EV/EBITDA of 20x, compared to 16x for regional and 15x for global peers. It justifies this premium valuation, citing the companies’ projected 2x EBITDA growth CAGR and 2x ROIC over the next three years, outperforming both regional and global counterparts.
Buy Piramal Pharma, target price Rs 340: JM Financial
JM Financial recommends buying Piramal Pharma stock. The target price is Rs 340. The current market price is Rs 260.55. India's CRDMO industry is expected to double by 2028. Piramal Pharma is well-positioned for growth. The company's CDMO business is a key driver. JM Financial projects a 15% topline growth and 23%+ EBITDA CAGR over FY24-27.
Sai Life Science grew fast, but pricing looks expensive
The issue gives a partial exit to private equity investors TPG Asia and HBM. The promoter share will be diluted from 41.8% to 35.2%. The issue proceeds are going to be used for repayment of borrowings.
India could account for 8-10 pc of work share outsourced to CDMOs by 2033: Report
India could take 8-10% of the global outsourcing share for Contract Research Development and Manufacturing Organisations by 2033 due to work shifting from the EU and the US to Asia. India and Korea are set to become key players, driven by geopolitical changes. Indian CDMOs are preparing to meet rising demand, particularly from US customers.
Load More
